SEOUL, Oct. 2 (Korea Bizwire) — SK bioscience Co., a biopharmaceutical arm of South Korea’s SK Group, said Wednesday it has completed its acquisition of a controlling stake in the German biotech company IDT Biologika. In June, the Korean company agreed to take over a 60 percent stake in IDT Biologika from Klocke Group for [...]
SEOUL, Jul. 25 (Korea Bizwire) — SK bioscience Co., a biopharmaceutical arm of South Korea’s SK Group, said Thursday it has agreed to invest US$2 million to acquire future shares in U.S. biotech company Sunflower Therapeutics. SK bioscience signed a simple agreement for future equity (SAFE) with Sunflower Therapeutics as part of efforts to expand [...]
SEOUL, Jun. 27 (Korea Bizwire) — SK bioscience Co., a biopharmaceutical arm of South Korea’s SK Group, said Thursday it has agreed to pay 339 billion won (US$243 million) for control of German biotech company IDT Biologika. The acquisition of IDT Biologika will give SK bioscience a crucial gateway for its expansion plans in the [...]
SEOUL, Dec. 12 (Korea Bizwire) — SK bioscience Co. said Tuesday it has started supplying Novavax’s updated COVID-19 vaccine to target the XBB.1.5 subvariant in South Korea. The vaccine, the only non-messenger RNA formulation against COVID-19 in the world, will be available for free at designated hospitals and health centers across the country starting next [...]
SEOUL, Aug. 24 (Korea Bizwire) — SK bioscience Co. said Thursday it has reached a deal with Vaxxas, an Australian biotechnology company, to jointly develop a new patch-type typhoid vaccine. The global charitable foundation Wellcome will fund the collaboration for the first two years, awarding US$3.67 million to conduct the first-phase clinical trial, according to [...]
SEOUL, Aug. 23 (Korea Bizwire) — SK bioscience Co., a pharmaceutical affiliate under South Korea’s SK Group, said Wednesday it will produce 5 million doses of its signature cell-based influenza vaccine SKYCellflu nationwide from next month for the coming winter season. It resumed the production two years after it had stopped manufacturing the prefilled syringe-typed [...]
SEOUL, Aug. 9 (Korea Bizwire) – SK bioscience Co., a pharmaceutical affiliate under South Korea’s SK Group, said Wednesday it has purchased 6.5 million shares in the U.S.-based biotechnology company Novavax Inc. for 110 billion won (US$83.4 million). With the stock purchase, SK bioscience will hold a 6.5 percent share in Novavax, according to the [...]
SEOUL, July 5 (Korea Bizwire) — SK bioscience Co., a pharmaceutical affiliate of South Korea’s SK Group, said Wednesday it has joined hands with Thailand’s state-run drugmaker to build vaccine manufacturing and development infrastructure in the Southeast Asian country. SK bioscience and Thailand’s Government Pharmaceutical Organization (GPO) signed a memorandum of understanding (MOU) on Tuesday, [...]
SEOUL, May 30 (Korea Bizwire) — SK bioscience Co., a pharmaceutical affiliate of South Korea’s SK Group, said Tuesday its COVID-19 vaccine SKYCovione has won approval from British authorities. The British Medicines and Healthcare products Regulatory Agency has approved the Korean vaccine for use as a primary vaccination in those aged 18 and over in [...]
SEOUL, April 28 (Korea Bizwire) — SK Bioscience Co., a pharmaceutical affiliate under SK Group, said Friday it will invest 2.4 trillion won (US$1.79 billion) by 2028 as it is seeking to further expand its contract manufacturing business. The proposed investment — twice the amount the company had spent in the past five years — [...]